Cambridge University graduates raise $3M to improve how decisions are made in pharma

LONDON, 2 September 2026 — Pharosyn, which builds AI infrastructure for commercial decision-making in pharma, has raised $3M in a fundraising round led by Moonfire. Investors include Entrepreneurs First, Transpose Platform and General Advance.

Pharosyn has spent months deploying their AI infrastructure deep into pharmaceutical commercial strategy workflows. Today, senior directors at top-10 pharmaceutical companies use Pharosyn every single day to inform major strategic decisions.

The results have been phenomenal. Critical insights delivered to senior decision-makers that would have otherwise been missed. Important questions answered in minutes instead of hours. Faster iteration creating compounding feedback loops and deeper analysis every week.

Pharosyn was founded by Stephen Cowley and Joshua Hampson, who brought Cambridge University backgrounds in AI research and biochemistry, both ranking in the top 5% of their cohorts. The team now carries years of engineering experience deploying AI in financial forecasting and enterprise productivity, alongside decades of senior executive experience consulting in pharmaceutical commercial strategy at Citeline and leading consulting firms.

Mattias Ljungman, Founder of Moonfire, commented: “Pharosyn’s founders are deeply technical, exceptionally tenacious and ambitious, and determined to be best-in-class globally. They are rare founders who clearly stand out. We could not be more excited to lead this round.”

Pharosyn is built on two convictions: that pharmaceutical companies need custom AI infrastructure to maintain a competitive advantage, and that embedding this infrastructure deep inside pharma teams can improve commercial decision-making. By dramatically increasing the depth of insight, scope of analysis and speed at which teams can work, Pharosyn helps companies make better decisions about where to allocate resources. Its infrastructure can be deployed across commercial strategy, portfolio strategy, business development & licensing, market research, forecasting and competitive intelligence.